Trial Selection Rising

EGFR L858R

gastric cancer · Combination Therapy

EGFR L858R is flagged as trial selection rising because public trials show inclusion required evidence in 5 contexts. FDA CDx context should be reviewed manually.

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 5

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 3

Common snippets: dMMR | dMMR | MSI-H

Threshold label: Moderate

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: High

Patent-density signal

Diagnostic appendix

Signal count: 0

Recent signals: 0

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT07689292 | https://clinicaltrials.gov/study/NCT01743365 | https://clinicaltrials.gov/study/NCT07266025 | https://clinicaltrials.gov/study/NCT05039944 | https://clinicaltrials.gov/study/NCT06038396